Drug Profile
Research programme: ER stress response modulators - Aravive
Alternative Names: 2-series; 4-series ER stressLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ruga Corporation
- Developer Aravive Biologics
- Class
- Mechanism of Action Cell physiology modulators; Protein folding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 15 Oct 2018 Aravive Biologics and Versartis merged to form Aravive
- 16 Jul 2016 No recent reports of development identified for research development in Multiple-myeloma in USA
- 22 May 2012 Early research in Multiple myeloma in USA (unspecified route)